The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

George S. Chrysant

University of Oklahoma College of Medicine

5850 West Wilshire Boulevard

Oklahoma City

OK, 73132

USA

[email]@yahoo.com

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of Oklahoma College of Medicine, 5850 West Wilshire Boulevard, Oklahoma City, OK, 73132, USA. 2012
  • Clinical Professor of Medicine, University of Oklahoma; Director, Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, OK. 2011
  • The Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma, USA. 2003 - 2011
  • Department of Cardiology and Hypertension, Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, Oklahoma City, USA. 2004 - 2010
  • University of Oklahoma, Oklahoma City, USA. 2010

References

  1. The Role of Angiotensin II Receptors in Stroke Protection. Chrysant, S.G. Curr. Hypertens. Rep. (2012) [Pubmed]
  2. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension. Chrysant, S.G. Postgrad. Med (2011) [Pubmed]
  3. Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination. Chrysant, S.G. Drugs. Today (2011) [Pubmed]
  4. Current status of dual Renin Angiotensin aldosterone system blockade for the treatment of cardiovascular diseases. Chrysant, S.G. Am. J. Cardiol. (2010) [Pubmed]
  5. Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. Chrysant, S.G., Lee, J., Melino, M., Karki, S., Heyrman, R. J. Hum. Hypertens (2010) [Pubmed]
  6. The role of Angiotensin receptor blocker and calcium channel blocker combination therapy in treating hypertension: focus on recent studies. Chrysant, S.G. Am. J. Cardiovasc. Drugs (2010) [Pubmed]
  7. The treatment of cardiovascular disease continuum: focus on prevention and RAS blockade. Chrysant, S.G., Chrysant, G.S., Chrysant, C., Shiraz, M. Curr. Clin. Pharmacol (2010) [Pubmed]
  8. Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. Chrysant, S.G., Chrysant, G.S. Am. J. Cardiol. (2010) [Pubmed]
  9. Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study. Chrysant, S.G. Clin. Drug. Investig (2010) [Pubmed]
  10. Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension. Chrysant, S.G., Murray, A.V., Hoppe, U.C., Dattani, D., Patel, S., Ritter, S., Zhang, J. Curr. Med. Res. Opin (2010) [Pubmed]
  11. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan. Chrysant, S.G. Drugs. Today (2010) [Pubmed]
  12. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. Chrysant, S.G., Oparil, S., Melino, M., Karki, S., Lee, J., Heyrman, R. J. Clin. Hypertens. (Greenwich) (2009) [Pubmed]
  13. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. Chrysant, S.G., Neutel, J.M., Ferdinand, K.C. J. Natl. Med. Assoc (2009) [Pubmed]
  14. Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. Chrysant, S.G. Expert. Rev. Cardiovasc. Ther (2009) [Pubmed]
  15. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study. Chrysant, S.G., Chavanu, K.J., Xu, J. Am. J. Cardiovasc. Drugs (2009) [Pubmed]
  16. Proactive compared with passive adverse event recognition: calcium channel blocker-associated edema. Chrysant, S.G. J. Clin. Hypertens. (Greenwich) (2008) [Pubmed]
  17. Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination. Chrysant, S.G. Drugs. Today (2008) [Pubmed]
  18. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Chrysant, S.G., Melino, M., Karki, S., Lee, J., Heyrman, R. Clin. Ther (2008) [Pubmed]
  19. Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum. Chrysant, S.G. Clin. Ther (2008) [Pubmed]
  20. Current and future status of beta-blockers in the treatment of hypertension. Chrysant, S.G., Chrysant, G.S., Dimas, B. Clin. Cardiol (2008) [Pubmed]
  21. Aliskiren-hydrochlorothiazide combination for the treatment of hypertension. Chrysant, S.G. Expert. Rev. Cardiovasc. Ther (2008) [Pubmed]
  22. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Chrysant, S.G., Murray, A.V., Hoppe, U.C., Dattani, D., Patel, S., Hsu, H., Zhang, J. Curr. Med. Res. Opin (2008) [Pubmed]
  23. Using fixed-dose combination therapies to achieve blood pressure goals. Chrysant, S.G. Clin. Drug. Investig (2008) [Pubmed]
  24. The pathophysiologic role of the brain renin-angiotensin system in stroke protection: clinical implications. Chrysant, S.G. J. Clin. Hypertens. (Greenwich) (2007) [Pubmed]
  25. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Chrysant, S.G., Sugimoto, D.H., Lefkowitz, M., Salko, T., Khan, M., Arora, V., Shi, V. Blood. Press. Suppl (2007) [Pubmed]
  26. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. Chrysant, S.G., Dimas, B., Shiraz, M. J. Hum. Hypertens (2007) [Pubmed]
  27. The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. Chrysant, S.G., Sugimoto, D.H., Lefkowitz, M., Salko, T., Khan, M., Arora, V., Shi, V. Blood Press. (2007) [Pubmed]
  28. The pleiotropic effects of angiotensin receptor blockers. Chrysant, S.G., Chrysant, G.S. J. Clin. Hypertens. (Greenwich) (2006) [Pubmed]
  29. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Chrysant, S.G., Marbury, T.C., Silfani, T.N. Blood. Press. Monit (2006) [Pubmed]
  30. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol. Chrysant, S.G., Ibrahim, M. J. Clin. Hypertens. (Greenwich) (2006) [Pubmed]
  31. Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases. Chrysant, S.G. Current. Clinical. Pharmacology (2006) [Pubmed]
  32. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. Chrysant, S.G., Chrysant, G.S., Desai, A. J. Hum. Hypertens (2005) [Pubmed]
  33. Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. Chrysant, S.G. J. Hum. Hypertens (2005) [Pubmed]
  34. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Chrysant, S.G., Weber, M.A., Wang, A.C., Hinman, D.J. Am. J. Hypertens. (2004) [Pubmed]
  35. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Chrysant, S.G., Chrysant, G.S. Expert. Opin. Pharmacother (2004) [Pubmed]
  36. Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. Chrysant, S.G., Bakris, G.L. Am. J. Hypertens. (2004) [Pubmed]
  37. Pharmacological and clinical profile of moexipril: a concise review. Chrysant, S.G., Chrysant, G.S. J. Clin. Pharmacol (2004) [Pubmed]
  38. Clinical experience with angiotensin receptor blockers with particular reference to valsartan. Chrysant, S.G., Chrysant, G.S. J. Clin. Hypertens. (Greenwich) (2004) [Pubmed]
  39. Stroke prevention with losartan in the context of other antihypertensive drugs. Chrysant, S.G. Drugs. Today (2004) [Pubmed]
  40. Has the role of calcium channel blockers in treating hypertension finally been defined?. Chrysant, G.S., Chrysant, S.G. Curr. Hypertens. Rep. (2003) [Pubmed]
  41. The ALLHAT study: results and clinical implications. Chrysant, S.G. QJM (2003) [Pubmed]
  42. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). Chrysant, S.G. Expert. Rev. Cardiovasc. Ther (2003) [Pubmed]
  43. Pharmacological profile and clinical use of moexipril. Chrysant, S.G., Chrysant, G.S. Expert. Rev. Cardiovasc. Ther (2003) [Pubmed]
 
WikiGenes - Universities